Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tri-VOICE plus: BNT162b2 booster after ChAdOx1-S vaccination in patients with cancer
2021-003573-58Phase 4Completed
- Sponsor
- Antwerp University Hospital
- Start
- Jul 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by Antwerp University Hospital. Primary endpoint: Change in SARS-CoV-2 IgG levels after third BNT162b2 dose. Started Jul 2021; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-003573-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003573-58.